Okay. Thanks so much for the introduction. I would like to welcome you all to this conference call, which will focus on our year-end report. Let's move to next slide two. This is just to confirm, as usual, the presentation does include some forward-looking statements. With that, we go to the next slide three. Let's start with the agenda. I and Marie will present the fourth quarter and year-end results 2020. We will also give a short pipeline update and some outlooks for 2021. The presentation will then be ended with a Q&A session. With that, we can move to slide four. This is a summary of the key highlights in 2020. During the year, Alligator increased our focus on clinical development and to reach major clinical inflection points with selective programs. Our focus programs are ATOR-1017 and mitazalimab. The decision to focus on ATOR-1017 and mita is based on their strong positioning. The positive data that supports a very competitive profile for the respective programs versus competitors, also on the fact that both programs are moving now into clinical phase II this year. Phase II is, of course, critical in the sense that a positive study greatly increases the chance to reach the market and overall is associated with significantly increased valuation, usually in the range of five times. To start with ATOR-1017. 1017 has raised through clinical phase I development. Despite the challenging patient recruitment environment during the pandemic, we have released interim data demonstrating good safety profile at therapeutic range dose levels, I should say, which is very promising considering the toxicities associated with the first-generation competitive products. We come back to this shortly. mitazalimab, or mita, has completed phase I. A recent data analysis was performed on patient gene expression material, that confirmed proof of mechanism in these patients. To put this in a simpler way, mita activates the immune system just the way it was designed to do. A thorough benchmark assessment has been performed versus key competitors, mita stands out with potential for superior clinical activity. Based on this, we took the decision to advance mita to clinical phase II in pancreatic cancer. This is a disease where CD40 has been clinically validated, we have submitted CTA for starting clinical phase II end of last year, with potential of start dosing in Q2. Last, Neo-X-Prime. This is a novel drug concept for more patient-specific immunotherapy. It builds on our leadership within dendritic cell therapies and our proprietary bispecific format, RUBY. The antibody identifies patient-specific cancer mutations, which is proteins that are generated only in that tumor, so-called neoantigens, and allows those neoantigens to be selectively presented to the immune system. This gives hope for greatly increased response rates in cancer treatment, and I'll go through that briefly during the presentation as well. Let's move to slide five. Next slide. This summarizes our key press releases during the fourth quarter of 2020. Apart from what I just mentioned for ATOR-1017 and mita, we also initiated preparations for bringing ALG.APV-527 to clinical phase, together with our co-development partner, Aptevo Therapeutics. This was on the back of positive clinical data from Aptevo's first program using the same bispecific platform. Apart from our clinical programs, we launched a novel antibody library, ALLIGATOR-FAB, and this is developed to act in concert with our internal bispecific format, RUBY. With that, our bispecific antibody platform is complete and provides a very efficient discovery engine that can continue to build on our track record on bringing novel products from IV to clinical phase. Let's move to our clinical candidates, our focus programs, and start with ATOR-1017, where we have an ongoing phase I study. Next slide six. ATOR-1017 is a leading second-generation immuno-oncology antibody designed for optimal efficacy. The format gives us potential for strong and tumor-selective immune activation. The objective here is to increase response rates, basically to have more patients benefiting from immunotherapy. There is a strong rationale for combining ATOR-1017 with our other T cell activating products, such as PD-1 or other checkpoint inhibitors. While PD-1 releases the brakes on T cells, ATOR-1017 pushes the gas. This is just as from core, it's much more likely that you get up to full speed if both are active at the same time. You need to release the brakes and push the gas. ATOR-1017 is currently in late phase I, and we are planning for presentation of clinical study data before the summer. We move to the next slide seven. The ongoing phase I study. It's a dose-escalation trial in metastatic cancer patients, terminal metastatic cancer patients, and safety is a primary endpoint, but also to select a dose for clinical phase II. In Q4, we cleared 100 mg or 1.5 mg per kg, which is expected to be in the therapeutic range. We are currently evaluating higher doses, and so far it looks very promising. Few drug-related side effects and mainly low-grade toxicity of those effects. This is important since the target has been associated with quite significant toxicity, and this is based on the first-generation products, including liver toxicity, which has been one of the major concerns. ATOR-1017 is a leading second-generation product within 4-1BB space, and is designed for a more tumor-selective activity to overcome just those issues. So far, it looks like we might be onto something important here. The data looks really promising with few significant side effects. We plan to present the phase I data at a conference before the summer, and the data set will include safety, tolerability, pharmacokinetics, and potential signs of efficacy, as well as a recommended phase II dose. Now, with that, I will move on to mitazalimab or mita. Slide eight. Next slide. Based on promising data from the phase I trial with mita, this is summarized to the left, a CTA for starting a clinical phase II trial was submitted by the end of the last year. This is a study in pancreatic cancer, and the first patient is expected to be recruited within a few months in Q2. We expect to be able to report initial data from the first handful of patients by the end of the year, and then to present a larger set of data at the end of 2022. Let's take a closer look on the study design, and this is in the next slide nine. Pancreatic cancer, this is a challenging indication, but given the clinical precedent for the target in pancreatic cancer, we believe that there is a good probability of seeing a response with mitazalimab. Sorry. The study is designed to build on the mechanism of action of CD40, and this is illustrated on the right-hand side. Patients will receive modified FOLFIRINOX, a chemotherapy cocktail, every two weeks. This is a chemo that will damage tumor cells and release tumor antigens. These tumor antigens will then be taken up by dendritic cells, and these are subsequently stimulated with mita to induce an immune response to these tumor antigens. This sequence of events is then repeated for every administration cycle of the chemotherapy. The selection of mFOLFIRINOX as a combination partner, this reflects the best-in-class properties of mita. mita is, again, a tumor-selected CD40 agonist antibody, and the tumor selectiveness allows for strong activation and better tolerability. We have, in fact, confirmed that while mita induces at least equal effects at the same dose levels as competitors, we have an advantage in that we can dose much higher. This has also been confirmed in our phase I trial. While our key competitors have been forced to select potentially subtherapeutic doses due to toxicity, mita can be dosed at the expected therapeutic dose range. This provides an opportunity, of course, for superior activity, and importantly, also allows for combination with more advanced and effective chemotherapy combinations like modified FOLFIRINOX. With that, we move on to slide 10. Apart from our clinical focus programs, I would like to bring up another drug development concept, Neo-X-Prime. This is a platform of bispecific antibodies that have potential to solve one of the great obstacles of immunotherapy today. That obstacle is the fact that four out of five patients are resistant to current immunotherapies. The low response rate is largely due to poor T cell priming. In other words, the immune system has difficulties in educating its effector parts, the T cells, to selectively attack tumor antigens. These tumor antigens are unique for each patient, that makes it extremely challenging. Neo-X-Prime solves this problem by binding to tumor material that's continuously being shed from the tumors of each patient, this is shown in the lower left graph of this slide. Neo-X-Prime physically brings that tumor material to the antigen-presenting cells for selective presentation and then activation of tumor-specific T cells. This concept holds the potential to induce strong immune responses, even in patients with very few tumor mutations. That is patients that otherwise would not be eligible for immunotherapy. It's interesting from a theoretical point of view, but the main reason why we are so enthusiastic about the concept is that it outperforms anything we have previously tested in our models. As an example to the right, we have a combination of two antibodies, compared to the same antibodies incorporated into the Neo-X-Prime prototype. The effect, as you can see, is amazing. We are currently in discussions with partner on potential co-development of Neo-X-Prime, and the ambition is to be able to develop our concept to the clinic with a partner, and that is to reduce our internal costs and to allow us to focus our internal resources on our two clinical focus programs, ATOR-1017 and mitazalimab. With that, I will leave it to Marie to walk you through our Q4 results and the recent share issue. We move to slide 11. In 2020, the group's net sales amounted to SEK 4.4 million, which pertains to the second license installment from the agreement with Biotheus. As Per touched on earlier, Alligator took this strategic decision during the spring to focus the company's resources on the projects that had the prospect of most rapidly generating the greatest value in the clinical program. As a result of this, the company's operating expenses during 2020 decreased by SEK 69 million versus 2019, corresponding to a reduction of more than 30%. The reduction in the company's expenses is mainly due to fewer employees in the company, that certain research projects have been suspended in favor of the clinical programs, and the conclusion of manufacturing of clinical study material. Expenses during the year were mainly related to the ongoing phase I clinical studies with ATOR-1015 and ATOR-1017, and preparations for the clinical phase II study with mitazalimab. Operating loss for the quarter amounted to SEK 34 million and SEK 144 million for the year. During the first quarter, the holdings in corporate bonds and interest funds were divested, which had a positive effect on the cash flow that you can see here in the table. Next slide, 12. The reduction in cost came into full effect in the third quarter 2020, which is reflected in the diagram to the left. At the end of 2020, Alligator's cash amounted to SEK 103.3 million. In order to continue pursuing our focus projects, mitazalimab and ATOR-1017, we carried out a right issue in January 2021 that generated proceeds of SEK 86 million before transactions cost. Our assessment is that the financial resources are sufficient for planned activities until Q2 2022. With that, I hand over back to Per. Okay. Thank you, Marie. Let's move on then to slide 13. This is the last slide. I would like to finish off with a summary of next important events. ATOR-1017 will continue dose evaluation during the spring, and that's in the ongoing phase I trial, and we plan to present the study data before the summer. Then we will proceed towards a phase II trial, which will be taking place in gastric cancer patients during the autumn. We will submit the CTA during the autumn and start the trial a few months later. mitazalimab is under CTA revision for starting a clinical phase II trial in pancreatic cancer, and we expect to be able to start dosing patients in the second quarter this year. That is within a few months. I will then conclude that we are advancing our clinical pipeline with two products entering a efficacy assessment in clinical phase II during the course of the year. With that, we are approaching important value inflection points for both these programs. With that, I would like to open up for questions. Thank you so much. Thank you. If you wish to ask a question, please dial zero one on your telephone keypads now to enter the queue. Once your name has been announced, you can ask your question. If you find it's answered before it's your turn to speak, you can dial zero two to cancel. So far we have one question in the queue, and that's from Ingrid Gafanhão of Kempen. Please go ahead. Your line is open. Hi. Good afternoon. Thank you for taking my questions. I have two, if I may. I just wanted to confirm, the data that we are expecting now for the phase I with ATOR-1017, are you planning to just issue a PR or should we expect to see something at a scientific conference? Yes. Both is correct, actually. We are planning to present it at a conference, hopefully that will be at ASCO in early June. We have submitted, we hope to get it approved for ASCO. We will also submit a press release when the abstract is to become published then. All right. That's very clear. A second question, I just wanted to confirm. In the phase II trial of mitazalimab in pancreatic cancer, it will be dosed IV, correct? Yes, that is correct. Okay. All right. No, that's very clear. Thank you very much. Thank you. Thank you. Once again, if there are any further questions, please dial zero one on your telephone keypads now. We've had one further question come through. That's from the line of Niklas Elmhammer of Redeye. Please go ahead. Your line is open Okay. Thank you, and good afternoon. Good afternoon. I was curious about mitazalimab. What are your plans for evaluating in combination with PD-1s? I guess that would be very natural at some point. Yes, that is absolutely true. We have a lot of the plans for PD-1. The reason why we start without PD-1 is basically that we want to make sure that we have activity by mitazalimab without PD-1, basically. That is to say that every combination with PD-1, there is always the suspicion that PD-1 is the major contributor to the effect. Once we have shown that mitazalimab has an effect by itself, even if it's combination with chemo, but the fact is with chemo, we know very well the expected response rates, so we can see an effect on top of that. We plan to add on PD-1. We hope to be able to do that rather soon. It's in the plans, but not while the study starts now in Q2. Okay, thank you. That's helpful. Looking at ATOR-1017, you perhaps could allude to what would a design for the next clinical trial look like, provided the ongoing trial is successful? Yeah, that is an important question, and I have many answers to that question. Actually, I would like to wait until we have decided upon the final design. We are looking at both first-line and second-line possibilities, and that, of course, leads to different combination regimens. Until we have a final decision on the selected design, I would like to wait and go after that at one time. Okay. That's understandable. Do you have any comments on the clinical benefits you have seen so far in the ongoing trial? On 1017? Yeah. 1017. Yes. The data that has been presenting so far, we have patients with quite long-standing stable disease, and that looks promising. We don't have any firm or confirmed responses in the released data yet. Hopefully, we can present something towards June, but that is too early to say anything about. Okay. Thank you. Finally, regarding ATOR-1015, if there are any activities going on there or any resources that you plan to use there. Well, we have reduced resources quite a lot in that program. There are still some patients on, but activity has been reduced quite a lot. As we have communicated during the autumn, we have run into some challenges with anti-drug antibodies, and that has also been associated with immune reactions. We are looking at ways to proceed despite those obstacles. It's something that is not the priority for us right now because we have quite limited resources, and we have two programs moving into phase II with mita and ATOR-1017. Because of these challenges, we have elected or decided to focus on those two programs, which are much more straightforward at the moment. Still, we hope to find a partner that would help us and to be able to invest in further study for that program. Right now, we are not investing ourselves. Okay, thank you. I'll move back into the queue. Thank you. Okay. Thanks so much. Thank you. Once again, if there are any further questions, please dial zero one on your telephone keypads now. Okay. There currently don't seem to be any further questions coming through on the phones at this point. Okay. I would like to thank everyone for joining this conference call and hope to meet soon again in the future. Thank you so much. Bye-bye. Thank you.